Background: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solventbased paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2þ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2þ tumors from the GeparSepto trial (n ¼ 396) in comparison to the HER2-cohort.
Introduction
Overexpression or amplification of human epidermal growth factor receptor 2 (HER2) is well established as a poor prognostic factor in breast cancer patients [1] . Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of HER2, has become an integral part of treatment of patients with HER2þ tumors, having demonstrated benefits in both early and metastatic settings [2, 3] . The newer monoclonal antibody pertuzumab binds HER2 at a different epitope of the HER2 extracellular domain from trastuzumab and prevents HER2 from dimerizing with other HER family members [4] . Recent studies have demonstrated improved outcomes with a dual HER2-targeted regimen of pertuzumab and trastuzumab [5, 6] . This approach achieved impressive rates of pathologic complete response (pCR) in two phase II neoadjuvant studies, NeoSphere [6] and TRYPHAENA [7] . The dual HER2-targeted regimen was more effective than either antibody alone as an adjunct to taxanebased chemotherapy [6] . As a result, pertuzumab received provisional approval from the US Food and Drug Administration and European Medicines Agency for neoadjuvant treatment in patients with HER2þ early-stage breast cancer.
Our recent randomized phase III GeparSepto trial (GBG 69; n ¼ 1206) demonstrated that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pCR rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for highrisk primary breast cancer. All 396 patients in GeparSepto who had HER2þ tumors received concurrent trastuzumab and pertuzumab. The present analysis compares detailed efficacy and safety data from the HER2þ, versus the HER2-, patients.
Patients and methods

Study design and conduct
Briefly, GeparSepto (NCT01583426) was a multicenter, prospective, randomized, open-label, phase III trial comparing nab-paclitaxel and standard paclitaxel as part of a neoadjuvant regimen. The study was approved by the ethics committees and patients provided written informed consent for study participation. Full details have been published previously [8] . Eligible patients had previously untreated breast cancer with tumors >2 cm (cT2-cT4a-d) and no additional risk factors or >1 cm with either clinical or pathological nodal involvement, classified (following central histology evaluation of core biopsy) as hormone receptor (HR)-negative (<1% immunohistochemical staining of the estrogenand/or progesterone protein), HER2þ (immunohistochemical staining either 3þ or 2þ with gene amplification 2), or Ki67 > 20%. Further eligibility criteria included left ventricular ejection fraction (LVEF) 55% and no metastases, known/suspected cardiac disease, previous thromboembolic event, preexisting peripheral sensory neuropathy grade 2, or significant gastrointestinal disease.
According to randomization, taxane treatment consisted of four 3-week cycles (days 1, 8, and 15) of either nab-paclitaxel or standard paclitaxel (80 mg/m 2 i.v.). After a planned interim safety analysis revealed an excess of treatment discontinuations and sensory neuropathies in the nab-paclitaxel arm, the dose was reduced from 150 to 125 mg/m 2 weekly. All patients subsequently received four 3-week cycles of EC (epirubicin 90 mg/m 2 i.v. on days 1-22 plus cyclophosphamide 600 mg/m 2 i.v. on day 1). Patients with HER2þ tumors received i.v. trastuzumab (8-mg/kg loading dose then 6 mg/kg) and pertuzumab (840 mg then 420 mg) q3w with each chemotherapy cycle. Trastuzumab was continued for a total of 1 year after surgery (see supplementary Figure S1 , available at Annals of Oncology online for study schema). Randomization was stratified by tumor subtype (HER2þ/HR-versus HER2þ/HRþ versus HER2-/HRversus HER2-/HRþ), Ki67, and SPARC (secreted protein acidic and rich in cysteine) status [9] . Treatment assignment was blinded to pathologists assessing surgery outcome and all local histopathological reports were subject to blinded central review by an independent pathologist. Tumor infiltrating lymphocytes (TILs) were evaluated as recently reported [10] .
Statistical methods
Objectives. Full details of the study objectives have been published previously [8] . For the present analysis, the aim was to assess the pCR rate of neoadjuvant trastuzumab-pertuzumab given concomitantly with nabpaclitaxel/paclitaxel-EC in patients with HER2þ breast cancer. The pCR rate among patients with HER2-disease treated in the same study (who did not receive anti-HER2 therapy) provided a reference. Secondary predefined aims included assessment of pCR rates by other definitions in the biological subtypes defined by HER2 and HR status and safety in the HER2þ versus HER2-cohort. It was expected to recruit approximately 400 HER2þ patients for the study.
Toxic effects reported as adverse events (AE) were based on NCI-CTCAE v4.0. Analysis is based on the (modified) intention-to-treat population-all patients who started study treatment after randomization. For the safety analysis, patients were evaluated according to whether or not they received anti-HER2 treatment ( Figure 1 ). Patients randomized within the window of opportunity substudy were included in the overall analysis and a sensitivity analysis excluding these patients was conducted.
As this was not a randomized comparison between patients with and without anti-HER2 treatment, statistical tests (two-sided Fisher's exact test) were carried out between HER2þ and HER2-groups for the safety, but not for efficacy (mainly descriptive), analysis. Patients with missing response data were considered as having no response. Multivariable analysis was carried out to identify predictive factors for pCR in trastuzumab-pertuzumab-treated HER2þ breast cancer. Efficacy parameters were reported in subgroups with two-sided 95% confidence intervals (CIs) and compared between treatment arms using continuity-corrected v 2 testing.
Results
Patients
A total of 1206 patients, 810 (67.0%) with HER2-and 396 (33.0%) with HER2þ breast cancer, started study treatment, 606 with nab-paclitaxel and 600 with standard paclitaxel ( Figure 1 ). As shown in supplementary Efficacy Table 1 shows achievement of pCR according to the FDAacknowledged pCR definitions ypT0 ypN0 (the primary endpoint) and ypT0/is ypN0 (a secondary endpoint), in patient subgroups by HER2 and/or HR status and taxane treatment group (supplementary Figure S2 , available at Annals of Oncology online).
Higher rates of pCR were achieved in HER2þ than in HER2-tumors (57.8% versus 22.0%). The highest rate (71.0% overall) was seen in patients with HER2þ/HR-tumors (n ¼ 83), with a pCR rate of 74.6% (63.5% to 85.7%) for patients treated with nab-paclitaxel and 66.7% (53.3% to 80.0%) for those who received standard paclitaxel (Table 1) . Multivariate regression analysis found the only significant predictor of pCR in HER2þ patients was a negative HR status [HR 2.05 (95% CI 1.23-3.41;
A similar pattern of responses was seen using the ypT0/is ypN0 definition for pCR (66.2% overall for HER2þ versus 25.2% for HER2-tumors with a 77.6% pCR rate in the HER2þ/HR-tumors [81.4% (71.4% to 91.3%) with nab-paclitaxel and 72.9% (60.3% to 85.5%) with standard paclitaxel].
A sensitivity analysis in the HER2þ cohort excluding the window-of-opportunity patients showed a pCR rate of 60.1% (52.5% to 67.8%) with nab-paclitaxel and 52.7% (45.1% to 60.2%) with paclitaxel (P ¼ 0.212).
Lymphocyte-predominant breast cancer (LPBC) predicted the odds of pCR (LPBC yes 54.3% versus LPBC no 15.6%: P < 0.001), in the HER2-, but not in the HER2þ (LPBC yes 61.7% versus LPBC no 57.1%; P ¼ 0.601), cohort.
Among the HER2þ patients 67.8% (61.3% to 74.3%) underwent breast-conserving surgery versus 70.4% (67.3% to 73.6%) of the HER2-group.
Tolerability
Overall, high-grade (3) AE (85.4% versus 78.0%; P ¼ 0.003) and nonhematologic AE (38.4% versus 30.1%; P ¼ 0.005) were more common in the HER2þ than in the HER2-group, but the rate of serious events (26.3% versus 22.1% of patients; P ¼ 0.112) was similar in the two groups (supplementary Table S2 , available at Annals of Oncology online). Of five deaths that occurred during therapy, only one was in the HER2þ cohort (standard paclitaxel group; see below). High-grade toxic effects that were significantly more common in the HER2þ patients included diarrhea (7.6% versus 0.9%; P < 0.001), dyspnea (2.5% versus <0.5%), mucositis/stomatitis/esophagitis (2.0% versus 0.5%), anorexia (1.0% versus 0.1%) and maculopapular rash (1.8% versus 0.5%) (all P < 0.05; Table 2 ).
As reported previously [8] , toxic effects and treatment discontinuations were more frequent with nab-paclitaxel than with standard paclitaxel. AE led to 10.6% of HER2þ and 11.5% of Figure 1 Disposition of Patients by HER2 status *Following a protocol amendment, HER2-positive patients (n ¼ 70) at selected sites were randomized to receive six weeks of trastuzumab, pertuzumab or both in combination, within a window of opportunity before chemotherapy. After an additional core biopsy patients entered the main phase of the study.
HER2-patients discontinuing taxane treatment and 2.3% of both cohorts discontinuing EC. Six patients (1.5%) discontinued pertuzumab before completing/discontinuing their chemotherapy because of AE (cardiac toxicity n ¼ 1; other nonhematologic toxicity n ¼ 5), whereas two patients discontinued both anti-HER2 agents (for cardiac toxicity and other nonhematologic toxicity, respectively).
Cardiac safety
LVEF decreases from baseline were more common in the HER2þ than in the HER2-patients (7.6% versus 4.9%; see sup plementary Table S3 , available at Annals of Oncology online), with 2.0% versus 0.4% of patients showing decreases to <50% and a 10% decrease from baseline ( Table 2 ). Only one patient (in the HER2þ group; aged 75 years with preexisting cardiac comorbidities) had a decrease to the 30 to <40% range and this patient died from heart failure. No decreases to <30% were recorded (supplementary Table S3 , available at Annals of Oncology online). Congestive heart failure (New York Heart Association, any grade) occurred in four patients (1.0%) in the HER2þ group versus two patients (0.2%) in the HER2-group (P ¼ 0.095), with grade 3-4 events in 3 (0.8%) versus 0 (0%) patients (P ¼ 0.035).
Discussion
Our prospective, randomized, multicenter, phase III GeparSepto study aimed to determine whether using nabpaclitaxel instead of the standard paclitaxel as part of a sequential neoadjuvant chemotherapy regimen for high-risk early breast cancer would improve patient outcomes. In the present analysis, we focus on efficacy and tolerability data from the HER2þ and HER2-subpopulations and present detailed pCR rates for the predefined subgroups. While pCR was consistently more common in patients treated with nab-paclitaxel, the difference reached statistical significance only in tumors that were HER2-and/or HR-negative. In contrast, the smaller ETNA study (n ¼ 695) did not find an advantage for nab-paclitaxel in HER2-breast cancer [11] .
Our 396 patients with HER2þ tumors received the dual HER2-targeted regimen of pertuzumab and trastuzumab in combination with chemotherapy. To facilitate comparison with findings from other studies, we analyzed pCR rates using both the ypT0 ypN0 and ypT0/is ypN0 definitions. The latter definition usually yields an approximately 10%-15% higher (absolute difference) pCR rate in HER2þ patients [12, 13] . pCR rates, but not the rate of breast-conserving surgery, were uniformly higher in HER2þ than in HER2-tumors (ypT0 ypN0 58% versus 22% and ypT0/is ypN0 66% versus 25% overall) and in HR-than in HRþ tumors, consistent with results from NeoSphere [6] and TRYPHAENA [7] . In NeoSphere, pertuzumab-trastuzumab-docetaxel (n ¼ 107 patients) achieved a significantly higher pCR rate (ypT0/is) (46%) than did trastuzumab-docetaxel (29%) or pertuzumab-docetaxel (24%) [6] . In other studies using this combination with neoadjuvant chemotherapy, TRYPHAENA [7] and the more recent KRISTINE study [14] , ypT0/is rates ranged from 56% to 66% NYHA ¼ New York Heart Association. [7, 14] and ypT0 ypN0 from 45% to 52% [7] . In I-SPY 2, ypT0 ypN0 rates of 54% (38%-70%) overall and 74% (53%-95%) in the HER2þ/HR-cohort were projected [15] . The pCR rates achieved in our GeparSepto HER2þ patients (66% overall ypT0/ is ypN0) compare favorably with rates reported in these studies and in others combining lapatinib with trastuzumab and anthracycline-containing neoadjuvant chemotherapy of 18 weeks' duration (47%-62%) [16] [17] [18] . In contrast to earlier data, with trastuzumab and lapatinib [10] , LPBC did not predict for a higher pCR rate in the HER2þ patients. A detailed meta-analysis is currently being conducted to investigate whether TILs are predictive for response to pertuzumab.
Achievement of pCR has been proposed as a surrogate for survival in breast cancer patients [19, 20] . Updated results from NeoSphere [21] showed that patients who received pertuzumabtrastuzumab-docetaxel had better 3-year progression-free survival (PFS; 90%) versus the control arms (81%-86%), consistent with this regimen having achieved the highest pCR rate. Pooled data from all four treatment arms also showed that DFS (HR 0.68; 95% CI 0.36-1.26) and PFS (HR 0.54; 95% CI 0.29-1.00) were significantly improved for patients who achieved pCR. Pertuzumab-trastuzumab with chemotherapy is currently being evaluated in the adjuvant phase III APHINITY study (NCT01358877). The results should provide important information on the survival benefits derived from this anti-HER2 combination.
Our HER2þ cohort experienced significantly more high-grade toxic effects than those with HER2-tumors. However, in contrast to reported experience with the TKIs, toxic effects appeared to have little effect on completion of HER2-targeted treatment, with <3% of patients discontinuing the treatment before their chemotherapy ended. The rate of grade 3 diarrhea in our HER2þ patients (8%) is higher than previously reported with pertuzumab-trastuzumab and chemotherapy in NeoSphere [6] but lower than rates seen with the dual anti-HER2 combination plus docetaxel-carboplatin in TRYPHAENA (12%) [7] and KRISTINE (15%) [14] . We also observed low rates of LVEF decreases (8%) and congestive heart failure (1%). Previous data suggest that adding pertuzumab to trastuzumab treatment does not increase the risk of cardiac dysfunction in patients receiving standard chemotherapy [5, 7] . In the cardiac safety study TRYPHAENA, LVEF decreases >10% resulting in LVEF <50% occurred in 7%-16% of patients receiving trastuzumab-pertuzumab in combination with various neoadjuvant chemotherapies, but LVEF recovered to 50% in all but one patient [7] . We do not have long-term cardiac toxicity data but as the odds ratio for developing a cardiac event with trastuzumab alone is 1.95, patients must be carefully monitored [22] and should not have preexisting cardiac comorbidities.
Limitations of the GeparSepto study have been discussed previously [8] . The trial was not specifically designed to evaluate anti-HER2 treatment and lacked a comparison arm treated with single HER2 blockade. Our data are nevertheless noteworthy, since we treated a large population of HER2þ patients with trastuzumab-pertuzumab and eight cycles of standard chemotherapy, a regimen which has not been evaluated previously. Indeed, because of the limited data available, current approval of the trastuzumab-pertuzumab combination for patients receiving neoadjuvant chemotherapy is limited to use with four to six cycles of chemotherapy [6] . All of our patients had high-risk breast cancer, as confirmed by central histopathology before randomization. Long-term data are not yet available but are being collected.
Thus, in patients with HER2þ early breast cancer, a dual HER2-targeted neoadjuvant combination of pertuzumab and trastuzumab, when given with sequential weekly (nab)paclitaxel and conventionally dosed EC, was well tolerated and achieved high rates of pCR, supporting its use as part of the neoadjuvant treatment regimen.
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